Shionogi Selected as a “DX Stock 2026”

OSAKA, Japan, April 10, 2026 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereinafter, "Shionogi") announced that Shionogi has been selected as a “Digital Transformation (DX) Stock 2026,” a designation jointly awarded by the Ministry of Economy, Trade and Industry (METI), the Tokyo Stock Exchange, Inc., and the Information-technology Promotion Agency, Japan (IPA), following its recognition as a “DX-Noteworthy Company” for three consecutive years.

The DX Stock program evaluates and selects companies that are transforming their business models and enhancing growth and competitiveness through digital transformation (DX), with digital technologies as a core premise. Shionogi was recognized for promoting its DX strategy in close alignment with its management strategy, strengthening company-wide capabilities in human resources, organizational structures, and digital platforms, and advancing operational reform and the creation of new value through the strategic use of data and artificial intelligence (AI).

Shionogi has identified the creation of new value through digital transformation as a key driver of its transformation, and is committed to strengthening its capabilities in data and AI across the organization. While continuing to build on its strengths as a research-driven pharmaceutical company, Shionogi is advancing its transformation into a Healthcare as a Service (HaaS) company by connecting its internal and external value chains through digital technologies, with the aim of contributing to a society where people can live longer, healthier, and more fulfilling lives.

Comment from Yosuke Miharu, Corporate Officer and Head of DX Promotion Division

“We are deeply honored that our efforts to date have been recognized through this selection as a DX Stock 2026. This recognition serves as a source of motivation, and we remain committed to pursuing further evolution toward the creation of new value. In our DX initiatives, what we must confront is not AI itself, but the speed of change. Going forward, we will design our operations, data, and IT platforms on the assumption of continuous change, and steadily convert new technologies, including generative AI, into company-wide competitiveness. By embedding DX as a mechanism that enhances the quality of business activities and decision-making, rather than limiting it to individual departments, we will ultimately be able to deliver pharmaceuticals and healthcare solutions that society needs more quickly.”

PDF

Shionogi Selected as a “DX Stock 2026”

Comment from Yosuke Miharu, Corporate Officer and Head of DX Promotion Division

Reference

Related Information

For Further Information, Contact: